$20.17
2.28% today
Nasdaq, Dec 04, 07:17 pm CET
ISIN
US0008991046
Symbol
ADMA

ADMA Biologics, Inc. Stock price

$19.72
+4.35 28.30% 1M
-0.74 3.62% 6M
+2.57 14.99% YTD
-0.20 1.00% 1Y
+16.48 508.64% 3Y
+17.75 901.02% 5Y
+10.46 112.96% 10Y
+11.17 130.64% 20Y
Nasdaq, Closing price Wed, Dec 03 2025
+0.47 2.44%
ISIN
US0008991046
Symbol
ADMA
Industry

New AI Insights on ADMA Biologics, Inc. Insights AI Insights on ADMA Biologics, Inc.

How does the company make money?
Who are the company’s main competitors?
What are the key opportunities and risks?
How is the company managed?

Key metrics

Basic
Market capitalization
$4.7b
Enterprise Value
$4.7b
Net debt
$11.0m
Cash
$61.4m
Shares outstanding
238.3m
Valuation (TTM | estimate)
P/E
23.2 | 32.6
P/S
9.6 | 9.1
EV/Sales
9.6 | 9.1
EV/FCF
115.8
P/B
10.9
Financial Health
Equity Ratio
71.4%
Return on Equity
56.6%
ROCE
32.6%
ROIC
47.0%
Debt/Equity
0.2
Financials (TTM | estimate)
Revenue
$488.6m | $516.3m
EBITDA
$167.1m | $218.1m
EBIT
$167.0m | $183.5m
Net Income
$209.5m | $144.2m
Free Cash Flow
$40.6m
Growth (TTM | estimate)
Revenue
27.6% | 21.1%
EBITDA
87.2% | 56.5%
EBIT
88.3% | 32.0%
Net Income
207.4% | -27.0%
Free Cash Flow
-48.5%
Margin (TTM | estimate)
Gross
54.7%
EBITDA
34.2% | 42.2%
EBIT
34.2%
Net
42.9% | 27.9%
Free Cash Flow
8.3%
More
EPS
$0.9
FCF per Share
$0.2
Short interest
9.6%
Employees
685
Rev per Employee
$620.0k
Show more

Is ADMA Biologics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,088 stocks worldwide.

ADMA Biologics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a ADMA Biologics, Inc. forecast:

9x Buy
90%
1x Hold
10%

Analyst Opinions

10 Analysts have issued a ADMA Biologics, Inc. forecast:

Buy
90%
Hold
10%

Financial data from ADMA Biologics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
489 489
28% 28%
100%
- Direct Costs 221 221
13% 13%
45%
267 267
43% 43%
55%
- Selling and Administrative Expenses 96 96
38% 38%
20%
- Research and Development Expense 3.78 3.78
102% 102%
1%
167 167
87% 87%
34%
- Depreciation and Amortization 0.12 0.12
78% 78%
0%
EBIT (Operating Income) EBIT 167 167
88% 88%
34%
Net Profit 209 209
207% 207%
43%

In millions USD.

Don't miss a Thing! We will send you all news about ADMA Biologics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

ADMA Biologics, Inc. Stock News

Positive
Seeking Alpha
14 days ago
ADMA Biologics remains a Buy as Q3 results and 2026 guidance support a bullish long-term outlook. ADMA's Asceniv drives robust revenue and margin expansion, with 2026 revenue guided at $630M and EBITDA margin at 56%. Yield-enhanced manufacturing and facility expansion position ADMA for further growth, while SG-001 offers optionality beyond 2029.
Neutral
Seeking Alpha
28 days ago
ADMA Biologics, Inc. ( ADMA ) Q3 2025 Earnings Call November 5, 2025 4:30 PM EST Company Participants Adam Grossman - Co-Founder, President, CEO & Director Brad Tade - CFO & Treasurer Conference Call Participants Anthony Petrone - Mizuho Securities USA LLC, Research Division Rick Miller - Cantor Fitzgerald & Co., Research Division Gary Nachman - Raymond James & Associates, Inc., Research Divisi...
Neutral
GlobeNewsWire
29 days ago
3Q 2025 Total Revenue of $134.2 Million, a 12% YoY Increase  3Q 2025 GAAP Net Income of $36.4 Million, a 1% YoY Increase 3Q 2025 Adjusted EBITDA (1) of $58.7 Million, a 29% YoY Increase 3Q 2025 Adjusted Net Income (2) of $38.9 Million, an 8% YoY Increase FDA Lot Release of First Yield-Enhanced Production Batches Positions ADMA for Margin Expansion Beginning in 4Q 2025 and Continuing Through 202...
More ADMA Biologics, Inc. News

Company Profile

ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in the manufacturing, marketing and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing, Plasma Collection Center, and Corporate. The ADMA BioManufacturing segment comprises of the immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The Corporate segment includes general and administrative overhead expenses. The company was founded by Adam S. Grossman and Jerrold B. Grossman on June 2, 2006 and is headquartered in Hackensack, NJ.

Head office United States
CEO Adam Grossman
Employees 685
Founded 2004
Website www.admabiologics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today